Genentech Asks A Lot From Avastin Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
The Avastin sponsor and FDA each submit their understandings of the central questions to be resolved at the June hearing on CDER's proposal to withdraw the breast cancer indication for bevacizumab.
You may also be interested in...
Roche Succeeds In Changing EMA Ruling On Avastin
The Committee for Medicinal Products for Human Use has reversed its previous rejection and is granting an indication for treatment of first-line breast cancer in combination with capecitabine.
Roche Succeeds In Changing EMA Ruling On Avastin
The Committee for Medicinal Products for Human Use has reversed its previous rejection and is granting an indication for treatment of first-line breast cancer in combination with capecitabine.
Genentech, CDER Tussle Over Avastin Hearing Panel And Format
In a sign of the uphill battle Genentech faces in retaining Avastin’s breast cancer claim, the company’s efforts to shape the panel and format for a June 28-29 hearing on the indication’s withdrawal are encountering strong opposition from FDA’s Center for Drug Evaluation & Research.